At the 2025 ASH Annual Meeting and Exposition, researchers presented new findings that may meaningfully affect how patients ...

Gastric cancer treatment can be especially challenging because patients often struggle with eating, maintaining weight, and ...

Living with chronic cancer involves balancing health precautions with the desire to enjoy life, especially during the ...

The SHARON trial is a phase 1 study testing a new treatment called GO-4 for patients with advanced pancreatic cancer who have ...

Treatment with bleximenib and Venclexta (venetoclax) showed a tolerable safety profile in a phase 1b trial for patients with ...

Shortly after beginning treatment for stage 3 inflammatory breast cancer, Lindsey Gunter started experiencing rare ...

The U.S. Food and Drug Administration (FDA) has granted fast track designation to muzastotug when used in combination with Keytruda (pembrolizumab) to treat adult patients with microsatellite stable ...

Bleximenib and Venclexta treatment were well tolerated in a phase 1b trial for relapsed/refractory acute myeloid leukemia with mostly low-grade side effects.

The FDA has granted breakthrough therapy designation to INCA033989 for some patients with essential thrombocythemia.

Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly.

Stage 4 metastatic breast cancer presents significant emotional and psychological challenges, requiring patients to adapt ...

Time and resilience have transformed the author's cancer experience into a fading memory, allowing life to return to normal.